Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 3, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 13, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-460934
Filed / recorded
Nov 13, 2026, 9:58 PM UTC
Added to OQRO
Nov 13, 2026, 10:00 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Obsidian Therapeutics, Inc.
Issuer CIK
2130606
Ticker
OBX
Reporting person
Julie B Feder
Relationship
Officer
Officer title
Chief Financial Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Aug 3, 2026
Transaction code
A
Shares / units
164,790
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
164,790
Ownership form
Direct
Amendment
No
Footnotes from the filing
The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vesting on January 12, 2027, the second installment vesting on February 3, 2027, and the remaining installments vesting each quarter thereafter, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.